Procter & Gamble Health (BOM:500126) Research & Development: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500126 Procter & Gamble Health Ltd BOM:500126
86 GF Score
Price ₹6,797.90
GF Value ₹6,049.27
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Procter & Gamble Health Research & Development?

Procter & Gamble Health BOM:500126 -0.76% 86 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,049.27 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Procter & Gamble Health's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Procter & Gamble Health  (BOM:500126) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Procter & Gamble Health Research & Development Related Terms

Procter & Gamble Health Research & Development Historical Data

* Premium members only.

The historical data trend for Procter & Gamble Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procter & Gamble Health Research & Development Chart

Procter & Gamble Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Jun21 Jun22 Jun23 Jun24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 39.30 65.50 57.10 38.60

Procter & Gamble Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:500126
86GF Score
Procter & Gamble Health Ltd BOM:500126
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procter & Gamble Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Procter & Gamble Health (BOM:500126) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Procter & Gamble Health and its competitors.
Is Procter & Gamble Health's Research & Development too high?
Procter & Gamble Health's current Research & Development is ₹0 Mil. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Research & Development compare to ZTS and UTHR?
Procter & Gamble Health's Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Procter & Gamble Health and its competitors. Procter & Gamble Health's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,049.27, compared to a current price of ₹6,797.90 — trading 12.4% above its estimated fair value. The current Research & Development is ₹0 Mil. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?

Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued. The current stock price of ₹6,797.90 is trading 12.4% above its estimated GF Value™ of ₹6,049.27. GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.

Key valuation signals for BOM:500126:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹6,049.27 vs. price of ₹6,797.90 (12.4% above fair value)
  • GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Procter & Gamble Health Business Description

Other Exchanges PGHL:India
Address Cardinal Gracias Road, Ground Floor And First Floor, P&G Plaza, Chakala, Andheri East, Mumbai, MH, IND, 400099
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score

Get the complete analysis for BOM:500126

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,797.90
Price
₹6,049.27
GF Value